ConductScience.org, home

Paper41363010

Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension.

Rossignol P and 10 others. Hypertension, 2026. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension. Papers, record 41363010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41363010

Download JSON
Disease
hypertensive disorder417 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension.
PubMed
Journal
Hypertension
PubMed
Year
2026
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
2.5, provisional
iCite
Revised in PubMed
2026-01-27
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rossignol PPatrickhttps://orcid.org/0000-0001-8009-3873
2Clozel MMartine
3Dreier RFRoland F
4Flack JMJohn Mhttps://orcid.org/0000-0003-2584-5598
5Flamion BBrunohttps://orcid.org/0000-0003-4458-7627
6Mann JJohannes
7Narkiewicz KKrzysztof
8Sassi-Sayadi MMouna
9Wang JGJi-Guanghttps://orcid.org/0000-0001-8511-1524
10Weber MAMichael Ahttps://orcid.org/0000-0002-8504-0831
11Schlaich MPMarkus Phttps://orcid.org/0000-0002-1765-0195

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
HypertensionMajor topic
Renal Insufficiency, ChronicMajor topic
Blood PressureMajor topic
Antihypertensive AgentsMajor topic
SulfonamidesMajor topic
Humans
Male
Female
Middle Aged
Double-Blind Method
Aged
Treatment Outcome
Single-Blind Method
Dose-Response Relationship, Drug
Drug Resistance
Pyrimidines

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03541174A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its SafetyDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References63

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121079049Predictive role of the nighttime blood pressure.Hypertension2011https://conductscience.org/library/papers/21079049PubMed
222670597Endothelin-1 and the kidney--beyond BP.Br J Pharmacol2012https://conductscience.org/library/papers/22670597PubMed
337495682GFR slope as a surrogate marker for future kidney failure.Nat Rev Nephrol2023https://conductscience.org/library/papers/37495682PubMed
436350038Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?Nephrology (Carlton)2023https://conductscience.org/library/papers/36350038PubMed
524952653Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.J Am Soc Hypertens2014https://conductscience.org/library/papers/24952653PubMed
631473020
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
Am J Kidney Dis2020https://conductscience.org/library/papers/31473020PubMed
730341579Prognostic value of estimated plasma volume in acute heart failure in three cohort studies.Clin Res Cardiol2019https://conductscience.org/library/papers/30341579PubMed
832897570Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet.Clin Pharmacol Ther2021https://conductscience.org/library/papers/32897570PubMed
933765691Endothelin receptor antagonists for pulmonary arterial hypertension.Cochrane Database Syst Rev2021https://conductscience.org/library/papers/33765691PubMed
1012671332The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?J Clin Hypertens (Greenwich)2003https://conductscience.org/library/papers/12671332PubMed
1123489784Brain natriuretic peptide and copeptin levels are associated with cardiovascular disease in patients with chronic kidney disease.Chin Med J (Engl)2013https://conductscience.org/library/papers/23489784PubMed
1222032706
Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
J Am Coll Cardiol2011https://conductscience.org/library/papers/22032706PubMed
1335772861Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.JACC Heart Fail2022https://conductscience.org/library/papers/35772861PubMed
1437053276Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease.Circ Res2023https://conductscience.org/library/papers/37053276PubMed
1535686330Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.J Clin Hypertens (Greenwich)2022https://conductscience.org/library/papers/35686330PubMed
1639656458Chlorthalidone vs Hydrochlorothiazide and Kidney Outcomes in Patients With Hypertension: A Secondary Analysis of a Randomized Clinical Trial.JAMA Netw Open2024https://conductscience.org/library/papers/39656458PubMed
1733912747N-Terminal Pro-B-Type Natriuretic Peptide and Incident CKD.Kidney Int Rep2021https://conductscience.org/library/papers/33912747PubMed
1839643698Endothelin receptor antagonists in chronic kidney disease.Nat Rev Nephrol2025https://conductscience.org/library/papers/39643698PubMed
1933409701Estimated plasma volume status in heart failure: clinical implications and future directions.Clin Res Cardiol2021https://conductscience.org/library/papers/33409701PubMed
2040811497
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Circulation2025https://conductscience.org/library/papers/40811497PubMed

See all 63 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42959198Endothelin antagonism: a new era for resistant hypertension.Clin Kidney J2026https://conductscience.org/library/papers/42959198PubMed
42707992Endothelin receptor antagonism for resistant hypertension in chronic kidney disease: where does aprocitentan fit?Clin Kidney J2026https://conductscience.org/library/papers/42707992PubMed
42644854Endothelin Receptor Antagonists in Resistant Hypertension and Proteinuric Kidney Disease: Receptor Strategy and Volume Management.J Clin Hypertens (Greenwich)2026https://conductscience.org/library/papers/42644854PubMed
42230805Aprocitentan in resistant hypertension with chronic kidney disease: balancing albuminuria reduction against early volume risk.J Hum Hypertens2026https://conductscience.org/library/papers/42230805PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213

Source NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
APROCITENTANCHEMBL2165326Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2165326

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41363010

GET https://conductscience.org/api/papers/v1/41363010/references?page=2